Stay updated with breaking news from Daptorum Group. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Regulatory News: Aptorum Group Limited , a clinical stage biopharmaceutical company dedicated to meeting unmet medical needs in oncology, autoimmune diseases and infectious diseases, today... | May 5, 2023
Regulatory News: Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) ("Aptorum Group" or "Aptorum"), a clinical stage biopharmaceutical company dedicated to meeting unmet medical needs in oncology
Aptorum Group saw its market capitalization double following a busy week where the biopharmaceutical firm released its latest results and announced a merger...
Regulatory News: Aptorum Group Limited , today announced that its wholly owned subsidiary Aptorum Therapeutics Limited has entered into a non-binding Letter of Intent and Term Sheet to merge ... | May 1, 2023
Aptorum Group Limited (NASDAQ:APM – Get Rating) was the recipient of a significant drop in short interest in the month of April. As of April 15th, there was short interest totalling 13,100 shares, a drop of 12.1% from the March 31st total of 14,900 shares. Approximately 1.4% of the shares of the company are short […]